Around 10% of patients with myasthenia gravis (MG) have no detectable MG antibodies (AChR or MuSK), known as seronegative MG. Hakan Cetin, MD, PhD, Medical University of Vienna, Vienna, Austria, comments on the next steps in this field needed to improve outcomes for seronegative patients. Some patients may be found as seronegative due to assay insensitivity. Alternatively, some patients may have an unrecognized congenital cause. Improved understanding of the mechanisms behind seronegative MG is a key research need. This interview took place during the European Academy of Neurology 2021 congress.